VRTX Vertex Pharmaceuticals Inc

Price (delayed)

$229.68

Market cap

$58.4B

P/E Ratio

27.28

Dividend/share

N/A

EPS

$8.42

Enterprise value

$53B

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather ...

Highlights
Vertex Pharmaceuticals's quick ratio has increased by 22% YoY
The gross profit has grown by 19% YoY and by 7% from the previous quarter
The price to earnings (P/E) is 60% less than the 5-year quarterly average of 68.0 but 20% more than the last 4 quarters average of 22.7
The EPS has declined by 19% year-on-year but it has increased by 10% since the previous quarter
VRTX's debt has soared by 60% YoY

Key stats

What are the main financial stats of VRTX
Market
Shares outstanding
254.25M
Market cap
$58.4B
Enterprise value
$53B
Valuations
Price to earnings (P/E)
27.28
Price to book (P/B)
6.25
Price to sales (P/S)
8.31
EV/EBIT
18.86
EV/EBITDA
18.08
EV/Sales
7.43
Earnings
Revenue
$7.13B
EBIT
$2.81B
EBITDA
$2.93B
Free cash flow
$1.92B
Per share
EPS
$8.42
Free cash flow per share
$7.44
Book value per share
$36.74
Revenue per share
$27.65
TBVPS
$43.5
Balance sheet
Total assets
$12.62B
Total liabilities
$3.09B
Debt
$876.8M
Equity
$9.53B
Working capital
$6.94B
Liquidity
Debt to equity
0.09
Current ratio
4.62
Quick ratio
4.21
Net debt/EBITDA
-1.84
Margins
EBITDA margin
41.1%
Gross margin
87.9%
Net margin
30.5%
Operating margin
37.2%
Efficiency
Return on assets
17.9%
Return on equity
23.9%
Return on invested capital
77.8%
Return on capital employed
26.3%
Return on sales
39.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VRTX stock price

How has the Vertex Pharmaceuticals stock price performed over time
Intraday
0.7%
1 week
-1.87%
1 month
2.79%
1 year
-3.33%
YTD
4.59%
QTD
4.59%

Financial performance

How have Vertex Pharmaceuticals's revenue and profit performed over time
Revenue
$7.13B
Gross profit
$6.27B
Operating income
$2.65B
Net income
$2.18B
Gross margin
87.9%
Net margin
30.5%
VRTX's net margin is down by 32% YoY but it is up by 2.3% QoQ
The gross profit has grown by 19% YoY and by 7% from the previous quarter
Vertex Pharmaceuticals's net income has decreased by 19% YoY but it has increased by 9% QoQ
VRTX's revenue is up by 19% YoY and by 7% QoQ

Growth

What is Vertex Pharmaceuticals's growth rate over time

Valuation

What is Vertex Pharmaceuticals stock price valuation
P/E
27.28
P/B
6.25
P/S
8.31
EV/EBIT
18.86
EV/EBITDA
18.08
EV/Sales
7.43
The price to earnings (P/E) is 60% less than the 5-year quarterly average of 68.0 but 20% more than the last 4 quarters average of 22.7
The EPS has declined by 19% year-on-year but it has increased by 10% since the previous quarter
The stock's price to book (P/B) is 47% less than its 5-year quarterly average of 11.9 but 4.2% more than its last 4 quarters average of 6.0
The equity has grown by 17% YoY and by 3.6% from the previous quarter
The price to sales (P/S) is 37% less than the 5-year quarterly average of 13.1
VRTX's revenue is up by 19% YoY and by 7% QoQ

Efficiency

How efficient is Vertex Pharmaceuticals business performance
The return on equity has declined by 37% year-on-year but it has grown by 4.8% since the previous quarter
VRTX's return on assets is down by 36% year-on-year but it is up by 7% since the previous quarter
The return on invested capital has declined by 23% year-on-year but it rose by 7% since the previous quarter
The return on sales has declined by 20% year-on-year but it has increased by 6% since the previous quarter

Dividends

What is VRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRTX.

Financial health

How did Vertex Pharmaceuticals financials performed over time
Vertex Pharmaceuticals's current ratio has increased by 24% YoY
Vertex Pharmaceuticals's quick ratio has increased by 22% YoY
VRTX's debt is 91% lower than its equity
VRTX's debt has soared by 60% YoY
The debt to equity rose by 29% YoY but it fell by 10% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.